Synonyms: BMN 111 | BMN-111
Compound class:
Peptide or derivative
Comment: Vosoritide is an investigational peptide analogue of C-type natriuretic peptide (CNP) with a longer half-life (duration of action) than the endogenous peptide [1]. It comprises the 37 C-terminal amino acids from human CNP with the addition of proline and glycine (PG) at its N-terminal.
Vosoritide represents a novel mechanism which has the potential to treat fibroblast growth factor receptor 3-driven achondroplasia [1-2]. HELM annotation: PEPTIDE1{P.G.Q.E.H.P.N.A.R.K.Y.K.G.A.N.K.K.G.L.S.K.G.C.F.G.L.K.L.D.R.I.G.S.M.S.G.L.G.C}$PEPTIDE1,PEPTIDE1,23:R3-39:R3$$$. |
Classification ![]() |
|
Compound class | Peptide or derivative |
International Nonproprietary Names ![]() |
|
INN number | INN |
10022 | vosoritide |
Synonyms ![]() |
BMN 111 | BMN-111 |
Database Links ![]() |
|
CAS Registry No. | 1480724-61-5 (source: WHO INN record) |
GtoPdb PubChem SID | 315661153 |
PubChem CID | 119058036 |
Search Google for chemical match using the InChIKey | IGYWDDBBJPSOTG-WBAGYEQSSA-N |
Search Google for chemicals with the same backbone | IGYWDDBBJPSOTG |
Search PubMed clinical trials | vosoritide |
Search PubMed titles | vosoritide |
Search PubMed titles/abstracts | vosoritide |
Search UniChem for chemical match using the InChIKey | IGYWDDBBJPSOTG-WBAGYEQSSA-N |
Search UniChem for chemicals with the same backbone | IGYWDDBBJPSOTG |